In the molecular architecture of liver cancer, a single protein called beta-catenin has been found to silence a critical tumor-restraining factor through two entirely separate pathways — one structural, one genetic — regardless of whether it carries cancer-driving mutations. Researchers studying hepatocellular carcinoma have traced the consistent loss of a protein called RND3 back to this dual suppression, illuminating why liver tumors so reliably acquire the capacity to spread. The discovery places RND3 at a crossroads of cell biology and cancer mechanics, suggesting that what has long appear
ß-catenin suppresses RND3 via distinct pathways in liver cancer
Two routes to silence the same gene, both leading to cancer spread
Mark
So beta-catenin suppresses RND3 in liver cancer. Why does that matter? Most people have never heard of RND3.
Mimi
Because RND3 loss correlates with the cancer spreading within the liver. When RND3 drops, the cancer gets worse at staying put.
Luke
But correlation isn't causation. Do we know that restoring RND3 would actually slow metastasis, or is it just a marker of what's already happening?
Mimi
That's the open question. The research shows the mechanism—how beta-catenin shuts RND3 down—but the therapeutic proof isn't there yet.
Mark
You said beta-catenin uses two different pathways. Why would cancer cells need two ways to do the same thing?
Mimi
That's elegant, actually. Wild-type beta-catenin uses the Hippo pathway. Mutant beta-catenin uses a microRNA called miR-512-3p. Two routes to the same destination.
Luke
Are both pathways active in the same tumor, or does a cell pick one or the other?
Mimi
The paper doesn't specify. That's another gap—we don't know if both mechanisms run simultaneously or if they're mutually exclusive depending on the cell's genetic state.
Mark
If RND3 is supposed to be a brake on cell movement, why would normal cells want to suppress it at all?
Mimi
Because RND3 suppression through the Hippo pathway in normal cells might be part of how tissues regulate their size and shape. It's not inherently cancerous—it's context-dependent.
Luke
So the problem isn't that beta-catenin suppresses RND3. The problem is that in cancer, this suppression goes unchecked and drives metastasis.
Mimi
Exactly. In normal liver, these pathways are balanced. In cancer, they're locked in the "off" position for RND3.
Le Pouls
- RND3, a protein that appears to act as a brake on tumor cell migration, is consistently silenced in hepatocellular carcinoma — and its loss tracks directly with cancer spreading through the liver.
- Beta-catenin, already implicated in liver cancer, turns out to suppress RND3 through not one but two distinct mechanisms, meaning the cancer has redundant routes to disable this restraint.
- In its normal form, beta-catenin works through the Hippo signaling pathway to repress RND3; in its mutated, oncogenic form, it deploys a microRNA called miR-512-3p to silence RND3 at the messenger RNA level.
- The existence of parallel suppression pathways suggests cancer cells have evolved to ensure RND3 stays off — a sign of how central this protein may be to controlling tumor behavior.
- Researchers now see RND3 as a potential therapeutic target, with combination strategies — disrupting the Hippo pathway alongside miR-512-3p inhibition — offering a way to restore its expression across different mutational backgrounds.
In the molecular architecture of liver cancer, a single protein called beta-catenin has been found to silence a critical tumor-restraining factor through two entirely separate pathways — one structural, one genetic — regardless of whether it carries cancer-driving mutations. Researchers studying hepatocellular carcinoma have traced the consistent loss of a protein called RND3 back to this dual suppression, illuminating why liver tumors so reliably acquire the capacity to spread. The discovery places RND3 at a crossroads of cell biology and cancer mechanics, suggesting that what has long appeared as one disease process is in fact the convergence of parallel molecular conspiracies toward the same destructive end.
Liver cancer is shaped by both genetic mutations and the physical forces cells exert on one another, and a protein called beta-catenin sits at the intersection of both. Beta-catenin performs two distinct cellular roles: it holds cells together as a structural scaffold, and it acts as a transcription factor that switches genes on or off. Researchers have now shown that regardless of which role it is playing, beta-catenin reliably suppresses a protein called RND3 — an unusual member of the Rho GTPase family — and that this suppression appears central to how hepatocellular carcinoma, the most common form of liver cancer, develops and spreads.
For years, scientists observed that RND3 levels fell in liver cancer without understanding why. Working with human tumor samples and laboratory cell lines, a research team discovered that beta-catenin silences RND3 through two entirely separate mechanisms. When beta-catenin is in its normal, unmutated state, it represses RND3 by engaging the Hippo pathway — a signaling cascade that ordinarily constrains cell growth. When beta-catenin carries cancer-driving mutations, a common occurrence in hepatocellular carcinoma, it takes a different route: it elevates a small regulatory RNA called miR-512-3p, which binds directly to RND3's messenger RNA and prevents the protein from being produced at all.
The parallel nature of these two pathways reveals something important about cancer's molecular logic. Both routes arrive at the same destination — diminished RND3 — yet operate through completely different machinery. The fact that tumors appear to have evolved redundant means of suppressing this single protein suggests RND3 plays a meaningful role in restraining malignant behavior. Its loss may explain why liver cancer cells shed their normal adhesion to neighboring cells and acquire the ability to migrate and invade surrounding tissue, a process tied to what researchers call mechanosensitivity — the cell's capacity to sense and respond to physical tension in its environment.
The findings carry therapeutic implications. Because beta-catenin suppresses RND3 regardless of its mutational status, restoring RND3 expression could represent a strategy that cuts across the genetic diversity of liver tumors. The dual-pathway mechanism also opens the door to combination approaches: agents targeting the Hippo pathway might be paired with inhibitors of miR-512-3p, creating a more complete blockade of RND3 suppression. For now, the research maps two distinct molecular routes by which beta-catenin transforms a normal liver cell into one capable of spreading — and places RND3 at the center of that transformation.
Liver cancer develops through a combination of genetic mutations and physical forces acting on cells, and a protein called beta-catenin sits at the center of both mechanisms. Beta-catenin has two distinct jobs in the cell: it acts as a structural scaffold holding cells together, and it functions as a transcription factor that switches genes on and off. Researchers have now shown that regardless of which role it plays, beta-catenin consistently suppresses a protein called RND3, an unusual member of a family of cellular regulators known as Rho GTPases. The finding matters because RND3 levels drop in hepatocellular carcinoma—the most common form of liver cancer—and that loss correlates with the cancer spreading within the liver.
For years, scientists knew that RND3 expression declined in liver cancer, but the molecular explanation remained opaque. A team working with human tumor samples and laboratory cell lines set out to understand how beta-catenin dysregulates RND3 in cancer. What they discovered was that beta-catenin suppresses RND3 through not one pathway but two, depending on the form of beta-catenin present. When beta-catenin exists in its normal, unmutated state, it represses RND3 transcription by working through the Hippo pathway, a cellular signaling cascade that controls cell growth and tissue size. But when beta-catenin carries cancer-driving mutations—a common event in hepatocellular carcinoma—it takes a different route. The mutated version downregulates RND3 by increasing levels of a small regulatory RNA called miR-512-3p, which then binds directly to RND3's messenger RNA and prevents the protein from being made.
The existence of these two parallel mechanisms reveals something fundamental about how cancer cells rewire their biology. Both pathways lead to the same outcome: less RND3 protein. Yet they operate through completely different molecular machinery. The wild-type pathway involves the Hippo signaling cascade, which normally acts as a brake on cell proliferation. The oncogenic pathway hijacks a microRNA system, a more direct form of gene silencing. The fact that cancer cells have evolved to suppress RND3 through multiple routes suggests the protein plays a critical role in restraining tumor behavior.
RND3 itself is an atypical member of its protein family. Unlike most Rho GTPases, which actively regulate cell movement and shape, RND3 appears to work differently—it may function as a brake on these processes rather than an accelerator. In the context of liver cancer, RND3 loss could explain why tumor cells lose their normal adhesion to one another and gain the ability to migrate and invade surrounding tissue. The protein may also be involved in what researchers call mechanosensitivity—the cell's ability to sense and respond to physical forces from its environment, particularly the tension created by cell-to-cell contacts.
The research was conducted on both human hepatocellular carcinoma samples and cultured cell lines, lending credibility to the findings across different experimental contexts. The researchers demonstrated that beta-catenin's suppression of RND3 occurs regardless of whether beta-catenin carries mutations, meaning this regulatory relationship is fundamental to how the protein drives liver tumorigenesis. This universality across mutational backgrounds suggests that targeting RND3 or restoring its expression might offer a therapeutic angle independent of a tumor's specific genetic mutations.
The implications extend beyond basic biology. If RND3 truly mediates the mechanosensitive dysfunction that allows cancer cells to detach and spread, then restoring RND3 expression or blocking the pathways that suppress it could potentially slow or reverse intrahepatic metastasis. The dual-pathway mechanism also raises the possibility of combination therapies: drugs that disrupt the Hippo pathway in normal cells might be paired with inhibitors of miR-512-3p in mutant cells, creating a more comprehensive blockade of RND3 suppression. For now, the research establishes RND3 as a key node in the network of molecular events that transform a normal liver cell into a metastatic cancer cell, and it maps two distinct routes by which beta-catenin orchestrates that transformation.
Citations marquantes
RND3 may constitute a key protein involved in the transcriptional program driven by oncogenic beta-catenin in HCC and as a mediator of the mechanosensitive response associated with cell-cell adhesion— Research findings from Nature study
Envie de l'histoire complète ?
Lire l'original sur Nature ↗